186 related articles for article (PubMed ID: 31487068)
1. New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances.
Simioni C; Bergamini F; Ferioli M; Rimondi E; Caruso L; Neri LM
Hematol Oncol; 2020 Feb; 38(1):22-33. PubMed ID: 31487068
[TBL] [Abstract][Full Text] [Related]
2. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
Kebriaei P; Poon ML
Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in Acute Lymphoblastic Leukemia.
Phelan KW; Advani AS
Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
[TBL] [Abstract][Full Text] [Related]
4. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
Pierro J; Hogan LE; Bhatla T; Carroll WL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
[TBL] [Abstract][Full Text] [Related]
5. Novel therapy for childhood acute lymphoblastic leukemia.
Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
[TBL] [Abstract][Full Text] [Related]
6. Agents in Development for Childhood Acute Lymphoblastic Leukemia.
Maloney KW; Gore L
Paediatr Drugs; 2018 Apr; 20(2):111-120. PubMed ID: 29143289
[TBL] [Abstract][Full Text] [Related]
7. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
8. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
Locatelli F; Moretta F; Rutella S
Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
[TBL] [Abstract][Full Text] [Related]
9. Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia.
Di Martino L; Tosello V; Peroni E; Piovan E
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445444
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
Ronson A; Tvito A; Rowe JM
Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted therapies in acute lymphoblastic leukemia.
Portell CA; Advani AS
Leuk Lymphoma; 2014 Apr; 55(4):737-48. PubMed ID: 23841506
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria as emerging targets for therapies against T cell acute lymphoblastic leukemia.
Olivas-Aguirre M; Pottosin I; Dobrovinskaya O
J Leukoc Biol; 2019 May; 105(5):935-946. PubMed ID: 30698851
[TBL] [Abstract][Full Text] [Related]
13. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
Maino E; Bonifacio M; Scattolin AM; Bassan R
Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
[TBL] [Abstract][Full Text] [Related]
15. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
Dias A; Kenderian SJ; Westin GF; Litzow MR
Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
[TBL] [Abstract][Full Text] [Related]
18. Response to Donadieu and Hill "Clinical trials in childhood acute lymphoblastic leukemia: a common prognostic classification and a common induction therapy are now warranted".
Gaynon PS
J Pediatr Hematol Oncol; 2002; 24(6):426-8. PubMed ID: 12218587
[No Abstract] [Full Text] [Related]
19. Clinical trials in childhood acute lymphoblastic leukemia: a common prognostic classification and a common induction therapy are now warranted.
Donadieu J; Hill C
J Pediatr Hematol Oncol; 2002; 24(6):424-5. PubMed ID: 12218586
[No Abstract] [Full Text] [Related]
20. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
